Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZX 100

X
Drug Profile

AZX 100

Alternative Names: AZX100

Latest Information Update: 22 Jul 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AzERx
  • Developer Capstone Therapeutics; OrthoLogic
  • Class Amino acids; Muscle relaxants; Peptides
  • Mechanism of Action Heat-shock protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Cerebral vasospasm; Pulmonary fibrosis; Scars; Vascular injuries

Most Recent Events

  • 26 Mar 2014 AZX 100 is available for licensing as of March 2014 (http://www.capstonethx.com)
  • 20 Jan 2012 Discontinued - Phase-II for Scars in USA (Intradermal)
  • 20 Jan 2012 Discontinued - Preclinical for Asthma in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top